Organisation paid for research Program year 2025 Source: CMS Open Payments

Suncoast Clinical Research

Neither a doctor nor a teaching hospital

Research payments

$17,294,920

4,282 payments

Through program year 2025, Suncoast Clinical Research is reported as receiving $17,294,920 in research payments, across 4,282 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$2,747,436	91
2024	Research	$3,026,056	307
2023	Research	$3,968,833	579
2022	Research	$2,638,045	704
2021	Research	$2,252,109	1,741
2020	Research	$1,005,097	553
2019	Research	$1,657,344	307

Breakdown

Who paid Research payments · program years 2019–2025

Eli Lilly and Company $14,152,337 241 payments
Novo Nordisk AS $1,003,726 3,614 payments
E.R. Squibb & Sons, L.L.C. $484,940 3 payments
Bayer HealthCare Pharmaceuticals Inc. $371,923 147 payments
AbbVie, Inc. $262,858 83 payments
AstraZeneca Pharmaceuticals LP $256,425 23 payments
GlaxoSmithKline, LLC. $241,779 112 payments
OraSure Technologies Inc. $186,855 13 payments
Welch Allyn $109,379 6 payments
Novartis Pharmaceuticals Corporation $93,841 4 payments

Studies the money was for Research payments · program years 2019–2025

Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimers Disease $1,878,576 11 payments
Assessment of Safety, Tolerability, and Efficacy Measured By Amyloid Reduction of Ly3372993 in Early Symptomatic Alzheimer's Disease $1,184,276 6 payments
Assessment of Safety Tolerability and Efficacy Measured By Amyloid Reduction of Ly3372993 in Early Symptomatic Alzheimer's Disease $1,081,217 2 payments
A Study of Donanemab (Ly3002813) in Participants With Early Alzheimer's Disease (Trailblazer-Alz 2) $609,389 3 payments
A Study of Different Donanemab (Ly3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (Trailblazer-Alz 6) $575,889 2 payments
Assessment of Safety, Tolerability, and Efficacy of Ly3372689 in Early Symptomatic Alzheimer's Disease $545,799 6 payments
Assessment of Safety, Tolerability and Efficacy of Ly3002813 Alone and in Combination With Ly3202626 in Early Symptomatic Alzheimers Disease $537,856 8 payments
A Phase 3 Randomized Double Blind Study to Investigate the Efficacy and Safety of Once Daily Oral Ly3502970 Compared With Placebo in Adult Participants With Obesity Or Overweight and Type 2 Diabetes (Attain-2) $457,559 4 payments
Ex9924-4473 $445,134 1,235 payments
Assessment of Safety Tolerability and Efficacy of Ly3372689 in Early Symptomatic Alzheimer's Disease $383,568 2 payments

What the money was spent on Research payments · program years 2019–2025

Other $109,379 6 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.